Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer

Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya 466-8560, Japan.
Anticancer research (Impact Factor: 1.83). 11/2006; 26(6B):4267-70.
Source: PubMed


Aberrant methylation of the CHFR gene associated with gene silencing has been reported in several primary tumors. In order to define the role of CHFR in the tumorigenic pathway of the colorectum, the methylation of CHFR was examined in tumors from colorectal cancer patients.
Ninety-eight colorectal cancer patients were examined using a methylation-specific PCR (MSP) for CHFR CpG island in primary tumors.
An aberrant methylation of the CHFR gene was detected in 25 out of 98 (26%) primary colorectal cancers. No methylation was detected in the corresponding normal tissue specimens. This finding suggested that an aberrant methylation of the CHFR gene occurs frequently in colorectal cancers. After a methylation analysis of all samples, the clinicopathological data were correlated with these results. A significant difference was found in the tumor (p = 0.035), thus, indicating that in early colorectal cancer the CHFR gene was more frequently methylated than in advanced cases.
These findings suggest that CHFR might act as a tumor suppressor in at least some colorectal cancers and that CHFR methylation might, therefore, be a particular phenomenon of early colorectal cancer.

Download full-text


Available from: Yasuhiro Kodera
  • Source
    • "In agreement with this idea, shRNA knock down of CHFR recently reported to induce the increased cell proliferation during the preparation of this manuscript [43]. Since the promoter methylation of the CHFR gene was detected in non-invasive adenoma lesions of colon epithelia [44], the associated loss of the checkpoint function of CHFR in these cells may have a significant impact upon the early stages of colon carcinogenesis. To gain further supportive evidence that the FHA domain of CHFR is important for its growth inhibition properties, we have recently put a considerable amount of effort into establishing a conditional expression system for this protein using the Cre-loxP recombination system [30] to evaluate tumor formation activity in vivo (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The CHFR protein comprises fork head associated- (FHA) and RING-finger (RF) domain and is frequently downregulated in human colon and gastric cancers up to 50%. The loss of CHFR mRNA expression is a consequence of promoter methylation, suggesting a tumor suppressor role for this gene in gastrointestinal carcinogenesis. In terms of the biological functions of CHFR, it has been shown to activate cell cycle checkpoint when cells are treated with microtubule depolymerizing agents. Furthermore, CHFR was reported to have E3 ligase activity and promote ubiquitination and degradation of oncogenic proteins such as Aurora A and polo-like kinase 1. However, molecular pathways involved in the tumor suppressive function of CHFR are not yet clear since the two established roles of this protein are likely to inhibit cell growth. In this study, we have identified that the FHA domain of CHFR protein is critical for growth suppressive properties, whereas the RF and cysteine rich domains (Cys) are not required for this function. In contrast, the RF and Cys domains are essential for E3 ligase activity of CHFR. By the use of a cell cycle checkpoint assay, we also confirmed that the FHA domain of CHFR plays an important role in initiating a cell cycle arrest at G2/M, indicating a functional link exists between the anti-proliferative effects and checkpoint function of this tumor suppressor protein via this domain. Collectively, our data show that the checkpoint function of the FHA domain of CHFR is a core component of anti-proliferative properties against the gastrointestinal carcinogenesis.
    Full-text · Article · Feb 2008 · PLoS ONE
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer can develop when genes that control the cell cycle and genomic stability are aberrantly expressed or non-functional. CHFR encodes an E3 ubiquitin ligase that reportedly delays mitosis in response to microtubule-targeting drugs (i.e. nocodazole and taxanes). Loss of CHFR mRNA expression has been reported in many cancers, including breast cancer, but the relevance of this to tumorigenesis remains unknown. To test if CHFR was relevant for mammary tumorigenesis, we analyzed the effects of altered expression in breast cancers. Nearly 40% of cultured and primary breast cancers had low or no CHFR, which was associated with large tumor size in patient samples. Decreased CHFR expression by RNAi in immortalized human mammary epithelial cell (IHMEC) lines resulted in taxane sensitivity and the acquisition of tumorigenic phenotypes including faster growth rates, higher mitotic indices, enhanced invasiveness and motility, epithelial-to-mesenchymal transitions, increased aneuploidy, and colony formation in soft agar. Conversely, over-expressing CHFR in breast cancer cells caused slower growth and decreased invasiveness and motility. To determine if CHFR was critical for genomic stability, cells transfected with CHFR siRNA were analyzed for chromosome segregation defects. Transient CHFR loss led to increased aneuploidy, misaligned metaphase chromosomes, anaphase bridges, multi-polar condensed spindles, multi-nucleated cells, and mislocalization of the mitotic checkpoint proteins MAD2 and BUBR1. CHFR was found to interact with three proteins required for mitotic spindle formation and chromosome segregation, including MAD2 and Aurora A where CHFR loss led to elevated Aurora A oncoprotein levels, but no change in MAD2 expression. Alpha-tubulin was identified as a novel target for CHFR-mediated ubiquitination and degradation after treatment with nocodazole. Decreased CHFR increased acetylated alpha-tubulin, a mitotic spindle protein implicated in cellular response to taxane treatment. These findings indicate that CHFR has tumor suppressive qualities and may be a biomarker for chemotherapeutic response to taxanes. CHFR has a previously unrecognized role as a regulator of genomic stability via its functional impact on BUBR1, MAD2, Aurora A, and alpha-tubulin. CHFR may be one of the few proteins that can control the cell cycle, chemotherapeutic response, and genomic stability - processes that go awry in breast cancer. Ph.D. Human Genetics University of Michigan, Horace H. Rackham School of Graduate Studies
    Full-text · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Checkpoint with FHA and RING finger domains (CHFR) was first recognized as an early mitotic checkpoint protein that delayed the cell cycle in response to microtubule-targeting drugs. It is an E3 ubiquitin ligase that ubiquitinates target proteins to direct them to the proteasome for degradation or to alter their activity. To date, however, the downstream target proteins critical to CHFR's normal cellular functions largely remain unidentified with the exception of the key mitosis regulators, and oncogenes, PLK1 and Aurora A kinases. Rapidly growing evidence in mice, primary human tumors, and mammalian cell culture models indicate that CHFR may also function as a potent tumor suppressor. Interestingly, studies reported to date suggest that CHFR both controls a novel prophase checkpoint early in mitosis and regulates chromosome segregation later in mitosis to maintain genomic stability. In addition, loss of CHFR sensitizes cancer cells to microtubule poisons, altering chemoresponsiveness to taxanes and making it a potential biomarker for chemotherapeutic response. Importantly, CHFR may be one of the few proteins that are required for regulating the cell cycle and maintaining genomic instability to inhibit tumorigenesis.
    Full-text · Article · Jul 2008 · Translational oncology
Show more